Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED) could improve cardiometabolic risk factors in women with metabolic syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome

NCT01806142

Metabolic Syndrome X

COMPLETED NA

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

NCT06461273

Diabetes Mellitus Metabolic Syndrome Obesity +4 more

ACTIVE_NOT_RECRUITING NA

Effects of Polyunsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin-resistant Men

NCT01934543

Metabolic Syndrome

COMPLETED NA

Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome

NCT00852475

Metabolic Syndrome

COMPLETED NA

An Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Subjects

NCT02148653

Metabolic Syndrome Insulin Resistance Overweight

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As the worldwide dietary pattern becomes more westernized, the metabolic syndrome is reaching epidemic proportions. Lifestyle modifications including diet and exercise are recommended as first-line intervention for treating metabolic syndrome. Previously, we reported that specific phytochemical supplementation for 12 weeks (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins) increased the effectiveness of the modified Mediterranean-style low glycemic load dietary program on variables associated with metabolic syndrome and CVD in subjects with metabolic syndrome and elevated LDL cholesterol. In this study, we propose to conduct a multi-center randomized trial to confirm our previous findings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Overweight Obesity Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-glycemic-load diet

Modified Mediterranean-style low-glycemic-load diet

Group Type ACTIVE_COMPARATOR

Low-glycemic-load diet

Intervention Type OTHER

Modified Mediterranean-style low-glycemic-load diet

Low-glycemic-load diet + medical food

Modified Mediterranean-style, low-glycemic-load diet + medical food

Group Type EXPERIMENTAL

UltraMealPlus 360 (Medical food)

Intervention Type DIETARY_SUPPLEMENT

Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)

Low-glycemic-load diet

Intervention Type OTHER

Modified Mediterranean-style low-glycemic-load diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UltraMealPlus 360 (Medical food)

Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)

Intervention Type DIETARY_SUPPLEMENT

Low-glycemic-load diet

Modified Mediterranean-style low-glycemic-load diet

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UltraMealPlus 360

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI ≥25 and \<45
* LDL \>100 mg/dl
* TG ≥150 and \<400 mg/dl
* meet 2 or more of the following 4 criteria:

* HDL \<50 mg/dl
* blood pressure ≥130/85 mmHg (or diagnosed hypertension on medication)
* fasting glucose ≥100 mg/dl and \<150 mg/dl
* waist circumference \>35 inches

Exclusion Criteria

* Medical History and Concurrent Diseases

1. Over the preceding 4 weeks, initiation or cessation of regular exercise
2. Over the preceding 4 weeks, involvement in a significant diet or weight loss program such as Atkin's diet program, a very low calorie liquid program (such as Optifast, Medifast, and HMR), or any diet that has led to a weight loss of 10% of body weight over a period of 6 weeks
3. Use of blood sugar lowering medications including thiazolidinedione class of oral medications including Avandia (rosiglitazone), Avandamet (metformin/rosiglitazone), Actos (pioglitazone), metformin (Glucophage, Fortamet, Riomet) or insulin over the preceding 12 weeks
4. Over the preceding 4 weeks, regular use of Kaprex® or Kaprex AI® at least 3 days/week
5. Over the preceding 4 weeks, regular use of NSAIDs (i.e. ibuprofen, celecoxib, etc.) at least 3 days per week
6. Over the preceding 12 weeks, use of cholesterol lowering medications, either by prescription (statins, etc.) or over-the-counter (gugulipids, niacin, etc.)
7. Over the preceding 12 weeks, use of oral or injectable corticosteroids, such as prednisone
8. Current use of oral anticoagulants such as Coumadin or injectable anticoagulants such as Heparin or Low Molecular Weight Heparin
9. Use of electronic implants such as pacemakers, defibrillators, nerve stimulators
10. Allergy to one or more of the ingredients in the investigational products
11. Poorly controlled hypertension (blood pressure above 155/95)
12. History of significant liver or kidney disease (recent or ongoing hepatitis, cirrhosis, glomerulonephritis, dialysis treatment, etc.)
13. History of serious heart disease (heart attack, angina, cardiac surgery, arrhythmia, or congestive heart failure)
14. History of deep vein thrombosis or pulmonary embolus (blood clot to lungs)
15. History of autoimmune diseases such as inflammatory bowel disease (Crohn's disease, and/or ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and thyroiditis
16. History of eating disorder (anorexia nervosa or bulimia) in preceding 5 years
17. History of alcoholism or drug addiction in the preceding 5 years
18. History of serious mental illness
19. History of attempted suicide in past 10 years
20. Untreated endocrine, neurological, or infectious disorder
21. Diagnosis of Human Immunodeficiency Virus (HIV) or Acquired HIV (AIDS)
22. Current cancer or a history of cancer (except skin cancer)
23. Pregnancy or lactation
24. If female of childbearing potential, unwillingness to practice a reliable method of birth control (i.e. physical sperm barriers or hormonal therapies)
25. Any other sound medical, psychiatric and/or social reason as determined by the Principal Investigator (PI).
* Physical and Laboratory Test Findings

1. TG ≥ 400 mg/dl
2. abnormal blood count (Hct \< 30 or \> 47%, WBC \< 3,000 or \> 12,000, platelets \<140 or \> 500)
3. abnormal kidney function test(s) (BUN \> 30 mg/dL or creatinine \> 1.5 mg/dL) or liver function test(s) (bilirubin total \> 2.0 mg/dL, ALT \> 75 IU/L, AST \> 75 IU/L; Alk Phos \> 130 IU)
4. fasting glucose \>150 mg/dL, serum calcium (\>10.5 mg/dL), positive pregnancy test (ß-hCG in blood)

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No